Grifols Doses First Patients In Two Phase 3 Trials To Expand Indications Of Immunoglobulins
GRFS•Trials for Gamunex-C and Xembify
- One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (IG) Gamunex®-C.
- The second trial, XPERT, will determine whether Grifols’ subcutaneous IG, Xembify®.
First patients dosed in two Phase 3 trials
Grifols SA said it has dosed the first patients in two Phase 3 trials to expand indications of its flagship immunoglobulins.
